Oral Genome is happy to announce the appointment of Michael Shuman as Chief Income Officer. Shuman brings in depth expertise main high-growth organizations within the dental business, most just lately serving as CEO of Membersy, the place he helped construct a nationwide footprint and drive industrial efficiency.
In his new position, Shuman will oversee industrial technique, enterprise development, and dental partnership growth to speed up the adoption of Oral Genome’s speedy, saliva-based testing nationwide.
“We’re thrilled to welcome Michael to Oral Genome,” mentioned Dr. Tina Noticed, Founder & CEO. “His observe document main transformational development aligns completely with our mission to carry preventive testing into each dental apply.”
“What drew me to Oral Genome is the mission of empowering suppliers to catch preventable points earlier than they begin,” says Michael Shuman, CRO. “I’ve spent my profession serving to dental organizations modernize the way in which they ship worth to sufferers, and Oral Genome represents the subsequent evolution of that journey. By combining scientific perception with scalable expertise, we’re making a pathway for each apply to play a proactive position in early detection and whole-body well being. I’m excited to assist increase entry and adoption throughout healthcare organizations nationwide.”
About Oral Genome
Oral Genome is a well being expertise firm pioneering saliva-based testing for oral and systemic well being. Its mission is to advance preventive care by making testing quick, accessible, and impactful for all.
Hepta, a biotech startup utilizing transformer-based AI to detect organ-specific indicators of persistent illness, emerged from stealth with $6.7 million in seed funding, in keeping with a press launch. Felicis Ventures and Illumina Ventures led the funding spherical. SeaX Ventures, Alumni Ventures, and AME Cloud Ventures additionally participated. The corporate was based by former Illumina, Grail and Google leaders who’re making use of the technological, genomic and commercialization knowhow from their liquid biopsy work to persistent illness.
Hamed Amini, co-founder and CEO of Hepta, defined its method to metabolic dysfunction-associated steatohepatitis (MASH).
“Our staff, which developed subsequent technology sequencing applied sciences at Illumina and constructed and scaled the primary technology of liquid biopsy platforms at Grail, has now demonstrated {that a} easy blood draw can replicate tissue-level biology. This establishes a basis for non-invasive diagnostics that may information precision therapies in persistent illnesses, beginning with MASH, a systemic metabolic illness and a worldwide epidemic affecting tens of hundreds of thousands within the U.S. alone, the place entry to care is tragically restricted by invasive, outdated or extremely specialised instruments. Past detection, our platform holds potential as a single supply for guiding remedy and monitoring response.”
To be taught extra, click on right here.
Amae Well being, a public profit company targeted on extreme psychological sickness, has raised a $25 million pre-empted Sequence B financing to remodel how extreme psychological sicknesses are understood, handled, and cured, in keeping with a press launch. Altos Ventures led the spherical with participation from all present buyers, together with Quiet Capital, Bling Capital, Cedars-Sinai Ventures, More healthy Capital, and 8VC.
The brand new funding will likely be used to assist the opening of Amae clinics nationwide, advance its proprietary AI-driven care platform, and assist analysis into schizophrenia, bipolar dysfunction, and treatment-resistant despair. It should additionally strengthen partnerships with educational medical facilities to increase entry to Amae’s built-in mannequin of care.
“Extreme psychological sickness devastates households and communities, but conventional remedy fashions haven’t moved the needle,” mentioned Stas Sokolin, Amae Well being co-founder and CEO. “We’re taking a unique path; combining compassionate, in-person care with responsibly deployed AI that helps clinicians decide the perfect course for every particular person.”
To be taught extra, click on right here.
Helex, a therapeutics firm growing a brand new class of focused medicines for genetic kidney illnesses, raised an oversubscribed $3.5 million Seed spherical, in keeping with a press launch. Investor pi Ventures led the spherical with participation from Bluehill Capital, SOSV, and a worldwide syndicate of buyers. Helex has raised over $6 million in complete funding thus far.
Helex needs to remodel the remedy of persistent and uncommon kidney problems by growing programmable non-viral lipid nanoparticle therapeutics that ship therapeutic cargo on to kidney cells. This method opens the door to a brand new class of focused, disease-modifying medicines for hundreds of thousands of sufferers who at present don’t have any efficient remedy choices.
Its lead program targets Autosomal Dominant Polycystic Kidney Illness, an inherited dysfunction, brought on by mutations within the PKD1 or PKD2 genes. The situation impacts greater than 12 million individuals worldwide, resulting in gradual formation of kidney cysts and decline in renal perform. Sufferers with ADPKD in the end face dialysis or kidney transplant. Helex goals to vary that with a single dose non-viral gene enhancing primarily based remedy that might halt or considerably gradual illness development.
To be taught extra, click on right here.
Picture: J Studios, Getty Pictures
It is a paid member function of MedCitizens. Please submit right here and be a part of!
